Arrowhead Pharmaceuticals (NASDAQ:ARWR) Earns "Buy" Rating from Chardan Capital

Chardan Capital reiterated their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR - Free Report) in a research report sent to investors on Tuesday morning,Benzinga reports. Chardan Capital currently has a $60.00 price objective on the biotechnology company's stock. Chardan Capital also issued estimates for Arrowhead Pharmaceuticals' FY2025 earnings at ($1.27) EPS and FY2026 earnings at ($3.44) EPS.

A number of other research firms have also weighed in on ARWR. HC Wainwright reaffirmed a "buy" rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a report on Wednesday, February 12th. B. Riley reaffirmed a "buy" rating and set a $38.00 price target (down from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $42.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $42.13.

Arrowhead Pharmaceuticals Trading Up 2.4%

Shares of ARWR stock traded up $0.37 during mid-day trading on Tuesday, reaching $15.71. The company's stock had a trading volume of 1,821,408 shares, compared to its average volume of 1,480,640. The company's 50 day simple moving average is $13.30 and its 200-day simple moving average is $17.80. Arrowhead Pharmaceuticals has a 12-month low of $9.57 and a 12-month high of $30.41. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27. The firm has a market capitalization of $2.17 billion, a PE ratio of -3.04 and a beta of 0.89.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The biotechnology company reported $2.75 earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $2.81. The firm had revenue of $542.71 million for the quarter, compared to analyst estimates of $116.27 million. During the same period in the previous year, the business posted ($1.02) earnings per share. On average, research analysts predict that Arrowhead Pharmaceuticals will post -2.42 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Christopher Richard Anzalone sold 51,425 shares of Arrowhead Pharmaceuticals stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $15.07, for a total value of $774,974.75. Following the completion of the transaction, the chief executive officer now directly owns 4,062,377 shares of the company's stock, valued at approximately $61,220,021.39. The trade was a 1.25% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders sold a total of 275,880 shares of company stock valued at $4,034,037 in the last ninety days. Corporate insiders own 4.30% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Empowered Funds LLC boosted its holdings in shares of Arrowhead Pharmaceuticals by 6.9% in the 1st quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company's stock valued at $194,000 after buying an additional 979 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of Arrowhead Pharmaceuticals by 34.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company's stock valued at $22,189,000 after buying an additional 447,456 shares during the period. Dynamic Technology Lab Private Ltd boosted its holdings in shares of Arrowhead Pharmaceuticals by 40.9% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 26,969 shares of the biotechnology company's stock valued at $343,000 after buying an additional 7,827 shares during the period. AQR Capital Management LLC acquired a new position in shares of Arrowhead Pharmaceuticals in the 1st quarter valued at about $514,000. Finally, ADAR1 Capital Management LLC boosted its holdings in shares of Arrowhead Pharmaceuticals by 336.4% in the 1st quarter. ADAR1 Capital Management LLC now owns 56,300 shares of the biotechnology company's stock valued at $717,000 after buying an additional 43,400 shares during the period. 62.61% of the stock is owned by institutional investors and hedge funds.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.